|
|
||||||||
Ann Thorac Surg 2007;84:1373-1374
© 2007 The Society of Thoracic Surgeons
a The Trauma Program and the Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
b Canadian Forces Health Services, Ottawa, Ontario, Canada
c St. Georges Hospital, University of London, London, United Kingdom
d Royal Army Medical Corps, British Army, London, United Kingdom
e Carbonear General Hospital, Newfoundland, Ottawa, Ontario, Canada
f Department of Critical Care Medicine, University of Ottawa, Ottawa, Ontario, Canada
Accepted for publication May 11, 2007.
* Address correspondence to Dr Tien, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Suite H186, Toronto, Ontario, M4N 3M5, Canada (Email: homer.tien{at}sunnybrook.ca).
Acute massive hemoptysis is a rare complication of pulmonary injury and contusion, and it is particularly difficult to manage in the nontertiary care setting. Recombinant activated coagulation factor VII (rFVIIa) is a prothrombotic drug that is increasingly being used to treat coagulopathy in massively exsanguinating trauma patients. We report a case in which recombinant activated coagulation factor VII successfully controlled massive hemoptysis and improved ventilation from a severe pulmonary contusion in a noncoagulopathic patient who suffered a penetrating thoracic injury in a military setting in Afghanistan.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |